Transgene SA

Transgene Provides Business and Financial Update for Q1 2025

24 Apr 2025 10:45:00 By Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

24 Apr 2025 01:00:00 By Nasdaq GlobeNewswire

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

23 Apr 2025 10:45:00 By Nasdaq GlobeNewswire

Availability of Transgene’s 2024 Universal Registration Document (URD)

10 Apr 2025 13:15:00 By Nasdaq GlobeNewswire

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

01 Apr 2025 10:45:00 By Nasdaq GlobeNewswire

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

27 Mar 2025 11:45:00 By Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

11 Mar 2025 11:45:00 By Nasdaq GlobeNewswire

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

06 Feb 2025 10:45:00 By Nasdaq GlobeNewswire

Transgene to Participate in the Biomed Forum Investor Conference

21 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2025

14 Jan 2025 10:45:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07 Jan 2025 11:00:00 By Nasdaq GlobeNewswire

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

07 Nov 2024 10:45:00 By Nasdaq GlobeNewswire

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

07 Nov 2024 10:45:00 By Nasdaq GlobeNewswire

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

05 Nov 2024 00:30:00 By Nasdaq GlobeNewswire

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

14 Oct 2024 00:30:00 By Nasdaq GlobeNewswire

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

07 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

24 Sep 2024 10:45:00 By Nasdaq GlobeNewswire

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

24 Sep 2024 10:45:00 By Nasdaq GlobeNewswire

2024 Half-Year Financial Report

24 Sep 2024 10:45:00 By Nasdaq GlobeNewswire

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

14 Sep 2024 02:05:00 By Nasdaq GlobeNewswire